Gt biopharma demonstrates novel b7-h3 targeting dual camelid nanobody bike and gtb-5550 induce nk cell activation against broad spectrum of tumors at esmo io congress 2021

Beverly hills, calif., dec. 8, 2021 /prnewswire/ -- gt biopharma, inc. (the "company") (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike® protein biologic technology platform, today announced that the company's mini-poster presentation abstract is now broadly available on the european society for medical oncology ("esmo") immuno-oncology ("io") congress 2021 abstracts webpage.
GTBP Ratings Summary
GTBP Quant Ranking